Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05248984 · ClinicalTrials.gov registry record · Phase 4
Dosing of Ketorolac Impacts Post-cesarean paiN manaGemenet (KING)
A Phase 4 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
NCT05248984: Completed Phase 4 study, sponsored by Ohio State University.
NCT05248984 is a Phase 4 study that has completed, run by Ohio State University. The registered enrollment target is 92 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05248984, a Phase 4 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a randomized controlled single blinded trial to compare the morphine milligram equivalents (MME) use in the first 24 hours postoperatively after cesarean section in patients receiving a single dose of 30 mg intravenous ketorolac vs. 60 mg intravenous ketorolac in the operating room after the end of surgery.
Primary Outcome
Comparing the morphine milligram equivalents (MME) use in the first 24 hours postoperatively after cesarean section in patients receiving a single dose of 30 mg intravenous ketorolac vs. 60 mg intravenous ketorolac in the operating room after the end of surgery.
Interventions
- DRUG Ketorolac 30 Mg
- DRUG Ketorolac 60 Mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2022-06-08 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 4 |
What the finished NCT05248984 record still lists
NCT05248984 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Ketorolac 30 Mg is the first listed.
NCT05248984 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05248984 about?
NCT05248984 is a clinical study titled "Dosing of Ketorolac Impacts Post-cesarean paiN manaGemenet (KING)". This is a randomized controlled single blinded trial to compare the morphine milligram equivalents (MME) use in the first 24 hours postoperatively after cesarean section in patients receiving a single dose of 30 mg intravenous ketorolac vs. 60 mg intravenous ketorolac in the operating room after the...
What is the current status of trial NCT05248984?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2022-06-08. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT05248984?
The interventions under investigation include: Ketorolac 30 Mg (DRUG), Ketorolac 60 Mg (DRUG).
Who is sponsoring clinical trial NCT05248984?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05248984's enrollment target sits among peer trials
92 876th of 2000 higher than 1,117 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI